UNSPSC 51291513: Toloxatone

This classification denotes an antidepressive agent, monoamine oxidase inhibitor, and oxazolidinone derivative with the molecular formula C11H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T206015T5, chemically known as 2-oxazolidinone, 5-hydroxymethyl-3-(m-tolyl)- but generally known as toloxatone, which bears US NIH Compound Identifier 34521. European Medicines Agency schedules Toloxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11169MIG.

UNSPSC 51291513 Toloxatone, a Commodity code, does not align with the state and local opportunities recently posted under this classification. The three documented solicitations—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's request for information on direct-to-manufacturer pharmacy programs, and MMCAP's multi-state RFP for generic pharmaceuticals and OTC products—address naloxone distribution, pharmacy benefit management, and broad pharmaceutical supply, respectively, rather than toloxatone specifically. The code as tagged appears misaligned with actual procurement activity; the opportunities suggest state and local governments are buying emergency opioid-reversal agents, pharmacy services infrastructure, and generic pharmaceutical supplies through county health departments, state health agencies, and cooperative purchasing alliances, but not toloxatone as a distinct line item.

Recent activity clusters around three jurisdictions and administrative structures: Seminole County, Florida (county health procurement); Texas Health and Human Services Commission (state agency); and Minnesota Multistate Cooperative Purchasing Alliance spanning Minnesota, Oregon, and member jurisdictions. Seminole County's IFB60459723LAS, posted June 30, 2026 with response due July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding with quarterly deliveries to its community health building in Sanford, Florida. Texas HHS issued RFI HHS0017013 on April 3, 2026 to gather vendor capability information on direct-to-manufacturer prescription programs prior to formal RFP issuance. MMCAP's cooperative purchasing RFP S1070000015802, due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products across state and local facilities, with contract effectiveness July 1, 2026. The geographic spread reflects Florida, Texas, and the Upper Midwest as centers of recent state and local pharmaceutical procurement activity, though the mismatch between the toloxatone code and the documented opportunities suggests limited decision-relevance for this specific commodity classification.